Prothena Corporation plc - Ordinary Shares (PRTA): Price and Financial Metrics

Prothena Corporation plc - Ordinary Shares (PRTA): $21.91

0.20 (+0.92%)

POWR Rating

Component Grades













Add PRTA to Watchlist
Sign Up

Industry: Biotech


of 485

in industry

PRTA Stock Summary

  • Prothena Corp Public Ltd Co's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 8.49% of US listed stocks.
  • PRTA's price/sales ratio is 1,017.73; that's higher than the P/S ratio of 99.21% of US stocks.
  • With a year-over-year growth in debt of -22.24%, Prothena Corp Public Ltd Co's debt growth rate surpasses just 15.07% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Prothena Corp Public Ltd Co, a group of peers worth examining would be VTGN, MRKR, KLDO, BCDA, and OTIC.
  • PRTA's SEC filings can be seen here. And to visit Prothena Corp Public Ltd Co's official web site, go to

PRTA Stock Price Chart Interactive Chart >

Price chart for PRTA

PRTA Price/Volume Stats

Current price $21.91 52-week high $27.20
Prev. close $21.71 52-week low $7.10
Day low $21.48 Volume 289,860
Day high $22.66 Avg. volume 461,036
50-day MA $15.74 Dividend yield N/A
200-day MA $12.64 Market Cap 876.12M

Prothena Corporation plc - Ordinary Shares (PRTA) Company Bio

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Latest News Stream

Event/Time News Detail
Loading, please wait...

PRTA Latest Social Stream

Loading social stream, please wait...

View Full PRTA Social Stream

Latest PRTA News From Around the Web

Below are the latest news stories about Prothena Corp Public Ltd Co that investors may wish to consider to help them evaluate PRTA as an investment opportunity.

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021

Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s diseaseNew pre-specified exploratory subgroup analyses and new digital biomarker data from Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease will be featured in two separate presentations DUBLIN, Ireland, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced three oral presentations and participation in a live forum at The 15th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2021). Prothen...

Yahoo | February 24, 2021

Prothena surges as Jefferies sees a 100% upside

Today Prothena Corporation ([[PRTA]] +28.7%) reached what could be its highest intraday gain in more than two years as Jefferies upgraded the stock to buy from neutral expecting a 100% upside to the stock.Citing the ‘positive momentum and pipeline execution’ and rising investor attention, the analyst Michael Yee ups the...

Seeking Alpha | February 12, 2021

Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today

Corvus Pharmaceuticals (NASDAQ: CRVS ) shares are … Full story available on

Benzinga | February 12, 2021

Prothena (NASDAQ:PRTA) Releases Quarterly Earnings Results, Meets Expectations

Prothena (NASDAQ:PRTA) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.77) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.77), MarketWatch Earnings reports. Prothena had a negative return on equity of 41.97% and a negative net margin of 13,615.75%. PRTA traded up $7.15 during midday trading on Friday, hitting […]

Transcript Daily | February 12, 2021

Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.

Yahoo | February 12, 2021

Read More 'PRTA' Stories Here

PRTA Price Returns

1-mo 99.18%
3-mo 99.18%
6-mo 64.86%
1-year 105.15%
3-year -35.25%
5-year -39.24%
YTD 82.43%
2020 -24.13%
2019 53.69%
2018 -72.53%
2017 -23.79%
2016 -27.78%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9114 seconds.